Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 153
News
News | 13 November 2021

Jubilant HollisterStier plans US $92 mn expansion

The 50,000 square foot expansion will house a high-speed filling line and lyophilizers, which will increase the facility’s sterile injectable capacity by 50%

News
News | 13 November 2021

Aster DM Healthcare PAT at Rs 107 cr. in Q2FY22

Aster DM Healthcare announced its financial results for the quarter ended September 30, 2021

News
News | 12 November 2021

Natco Pharma PAT at Rs 65.1 cr. in Q2FY22

Natco Pharma has reported consolidated financial results for the period ended September 30, 2021

News
News | 12 November 2021

World’s first Whole Genome Sequencing study uncovers new and potential therapies

The ground-breaking project, led by Genomics England and NHS England, was established in 2013 to sequence 100,000 whole genomes from NHS patients and their families

News
News | 12 November 2021

Covaxin well tolerated with no safety concerns: Lancet

Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%

News
News | 12 November 2021

Solara Active Pharma Sciences PAT slides to Rs 29.71 cr in Q2FY22

Solara Active Pharma Sciences has reported consolidated financial results for the period ended September 30, 2021.

News
News | 12 November 2021

J.B Chemicals & Pharmaceuticals PAT at Rs 98 cr. in Q2FY22

J. B. Chemicals & Pharmaceuticals Limited (JBCPL), announced its financial results for the second quarter ended 30th September, 2021

News
News | 11 November 2021

Alembic Pharma PAT at Rs 169.29 cr. in Q2FY22

The Board of Directors of Alembic Pharmaceuticals have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021.

News
News | 11 November 2021

Metropolis Healthcare PAT at Rs 58.26 cr in Q2FY22

Metropolis Healthcare has reported consolidated financial results for the period ended September 30, 2021

News
News | 11 November 2021

Hester Biosciences to acquire 50 % stake in Thrishool Exim, Tanzania

The consideration for the acquisition is US $ 2.25 million

News
News | 11 November 2021

Clinical study shows ViroStop spray prevents Covid-19

Evidence also shows better immune response to virus among users of spray

News
News | 10 November 2021

Moderna seeks approval from EMA for its Covid-19 vaccine for children between 6-11 years

The submission is based on Phase 2/3 study of mRNA-1273 in children ages 6 to 11

News
News | 10 November 2021

US govt places additional order of 1.4 million courses of molnupiravir

Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults

News
News | 10 November 2021

Pulmatrix resolves dispute with Cipla

Cipla Technologies a subsidiary of Cipla and Pulmatrix had inked a definitive agreement for the co-development and commercialisation of Pulmazole.

News
News | 10 November 2021

India Pharmaceutical Market grows 5% in October 2021

Ind-Ra continues to expect IPM’s revenue to grow over 12% yoy in FY22

News
News | 10 November 2021

AstraZeneca Pharma India PAT at Rs 11.94 cr. in Q2FY22

The Board of Directors of AstraZeneca Pharma India have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021

News
News | 10 November 2021

Marksons Pharma PAT slips to Rs 46.28 in Q2FY22

Marksans Pharma has reported consolidated financial results for the period ended September 30, 2021

News
News | 10 November 2021

Strides Pharma Science incurs Rs 162.55 cr. loss in Q2FY22

Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021

News
News | 09 November 2021

Wockhardt PAT at Rs 33.53 cr. in Q2FY22

The Board of Directors of Wockhardt have approved the unaudited consolidated financial results for the period ended September 30, 2021.

News
News | 09 November 2021

Aurobindo Pharma PAT drops to Rs 696.99 cr in Q2FY22

The Board of Directors of Aurobindo Pharma have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021

Startup

Digitization